Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

Long COVID affects an estimated 65 million people worldwide and can damage the brain, heart, blood vessels, and immune system ...

Biocon Biologics to launch Trastuzumab, Nivolumab, Pembrolizumab biosimilars for cancer. Expanding oncology portfolio.

Ascidian Therapeutics ("Ascidian"), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

The study, published in the latest issue of the Proceedings of the National Academy of Sciences (PNAS), was led by ...

BrightInsight, Inc. ('BrightInsight”), a leader in digital health solutions, today shared new data from its collaboration with Sanofi and its partner, Regeneron, highlighting the positive impact of ...

The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...

A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual ...

Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

Earthworms remove 70-95 percent of antibiotic resistance genes from farm manure, making safer fertilizer for crops.

Oceanside, CA - January 07, 2026 - PRESSADVANTAGE - Moment of Clarity has published a new educational resource ...